Axon Enterprise, Inc. (NASDAQ:AXON) Director Julie A. Cullivan Sells 657 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Julie A. Cullivan sold 657 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $700.00, for a total transaction of $459,900.00. Following the sale, the director now directly owns 1,735 shares of the company’s stock, valued at approximately $1,214,500. This trade represents a 27.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Axon Enterprise Stock Up 4.6%

Shares of AXON opened at $724.77 on Wednesday. The company has a market cap of $56.42 billion, a PE ratio of 187.28, a P/E/G ratio of 5.17 and a beta of 1.24. The business has a fifty day moving average of $572.18 and a 200 day moving average of $588.52. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $732.17. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. Axon Enterprise’s revenue was up 31.3% on a year-over-year basis. During the same period last year, the company earned $1.15 earnings per share. On average, sell-side analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Institutional Trading of Axon Enterprise

A number of institutional investors have recently bought and sold shares of AXON. Northern Trust Corp increased its stake in Axon Enterprise by 1.2% in the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company’s stock worth $381,692,000 after purchasing an additional 8,794 shares during the period. Brooklyn Investment Group increased its stake in Axon Enterprise by 20.5% in the first quarter. Brooklyn Investment Group now owns 441 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 75 shares during the period. TriaGen Wealth Management LLC increased its stake in Axon Enterprise by 852.8% in the first quarter. TriaGen Wealth Management LLC now owns 3,754 shares of the biotechnology company’s stock worth $1,974,000 after purchasing an additional 3,360 shares during the period. Versor Investments LP increased its stake in Axon Enterprise by 597.8% in the first quarter. Versor Investments LP now owns 2,798 shares of the biotechnology company’s stock worth $1,472,000 after purchasing an additional 2,397 shares during the period. Finally, Berkshire Capital Holdings Inc. increased its stake in Axon Enterprise by 157,600.0% in the first quarter. Berkshire Capital Holdings Inc. now owns 15,770 shares of the biotechnology company’s stock worth $8,294,000 after purchasing an additional 15,760 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research analyst reports. The Goldman Sachs Group increased their price objective on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Needham & Company LLC increased their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. JMP Securities reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. Finally, Barclays increased their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $640.91.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.